Journal profile · CELL & TISSUE ENGINEERING-CELL BIOLOGY
Current Stem Cell Research & Therapy
ISSN 1574-888X · eISSN 2212-3946 · Bentham Science Publishers B.V. · U ARAB EMIRATES
Current Stem Cell Research & Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.98; subscription journal; median 116 days to acceptance (52 articles, last 24 months); community-reported acceptance: fairly easy; 54 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Stem Cell Research & Therapy is published by Bentham Science Publishers B.V. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Mesenchymal stem cell research, Pluripotent Stem Cells Research and Tissue Engineering and Regenerative Medicine, together about 45.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Current Stem Cell Research & Therapy publishes high quality frontier reviews, drug clinical trial studies and guest edited issues on all aspects of basic research on stem cells and their uses in clinical therapy. The journal is essential reading for all researchers and clinicians involved in stem cells research.
Source: LetPub
Research area (LetPub): CELL & TISSUE ENGINEERING-CELL BIOLOGY
Main research topics OpenAlex counts of recent articles; shares are approximate
- Mesenchymal stem cell researchMedicine25.4%
- Pluripotent Stem Cells ResearchBiochemistry, Genetics and Molecular Biology11.1%
- Tissue Engineering and Regenerative MedicineMedicine9.1%
- Cancer Cells and MetastasisMedicine4.5%
- Periodontal Regeneration and TreatmentsMedicine4.2%
- Electrospun Nanofibers in Biomedical ApplicationsMaterials Science3.9%
- Extracellular vesicles in diseaseBiochemistry, Genetics and Molecular Biology3.9%
- Biomedical Ethics and RegulationMedicine3.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cell & Tissue Engineering | Zone 4 |
| Minor | Cell Biology | Zone 4 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cell & Tissue Engineering | Zone 4 |
| Minor | Cell Biology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Cell & Tissue Engineering | Zone 4 |
| Minor | Cell Biology | Zone 4 |
Top journal: noReview journal: yes
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.98LetPub ·
- CiteScore 2026-06
- 4.2LetPub ·
- SJR 2026-06
- 0.54LetPub ·
- SNIP 2026-06
- 0.47LetPub ·
- h-index
- 43LetPub ·
- h-index
- 72OpenAlex ·
- i10-index
- 702OpenAlex ·
- 2-year mean citedness
- 1.55OpenAlex ·
- Self-citation rate
- 4.8%LetPub ·
- Share of gold OA articles
- 3.9%LetPub ·
Volume
- Articles per year
- 62LetPub ·
Articles by year OpenAlex count · 1,484 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 45 | 1 | 5 |
| 2025 | 54 | 6 | 70 |
| 2024 | 83 | 4 | 208 |
| 2023 | 117 | 8 | 633 |
| 2022 | 140 | 3 | 993 |
| 2021 | 93 | 6 | 876 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
116 daysMedian, submission to acceptance · P25–P75 90 days – 135 days
- Acceptance to online
- median 203 days (52 articles)
- Submission to online
- median 317 days
- Sample
- 52 articles with submission and acceptance dates (196 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Bentham Science Publishers B.V.
- Country or region
- U ARAB EMIRATES
- Language
- English
- ISSN
- 1574-888X
- Electronic ISSN
- 2212-3946
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Stem Cell Research & Therapy
What CAS zone is Current Stem Cell Research & Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Stem Cell Research & Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Cell & Tissue Engineering / Cell Biology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Stem Cell Research & Therapy?
The latest impact factor listed by LetPub is 1.98; CiteScore 4.2, h-index 72.
How long does peer review take at Current Stem Cell Research & Therapy?
Based on the dates recorded on 52 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 116 days (interquartile range 90–135 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Current Stem Cell Research & Therapy?
According to LetPub and DOAJ records, Current Stem Cell Research & Therapy is indexed in SCIE and Scopus.
Is Current Stem Cell Research & Therapy open access, and what is the APC?
Current Stem Cell Research & Therapy is a subscription journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .